NICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends in deals that play a role in NICE recommendations made.
There has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for Health and Care Excellence (NICE), has said when it comes to cancer
With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health
Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed over it’s 20-year history and what the future might hold.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.